Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
3.930
+0.040 (1.03%)
At close: Aug 24, 2026, 4:00 PM EDT
4.067
+0.137 (3.48%)
After-hours: Aug 24, 2026, 7:30 PM EDT
Cyclerion Therapeutics Employees
Cyclerion Therapeutics had 1 employees as of June 30, 2026. The number of employees did not change compared to the same quarter last year.
Employees
1
Change
n/a
Growth
n/a
Revenue / Employee
$1,900,000
Profits / Employee
-$6,707,000
Market Cap
18.11M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 1 | 0 | - |
| Mar 31, 2026 | 1 | 0 | - |
| Dec 31, 2025 | 1 | 0 | - |
| Sep 30, 2025 | 1 | 0 | - |
| Jun 30, 2025 | 1 | 0 | - |
| Mar 31, 2025 | 1 | 0 | - |
| Dec 31, 2024 | 1 | 0 | - |
| Sep 30, 2024 | 1 | 0 | - |
| Jun 30, 2024 | 1 | - | - |
| Mar 31, 2024 | 1 | -15 | -93.75% |
| Dec 31, 2023 | 1 | -15 | -93.75% |
| Dec 31, 2022 | 16 | -16 | -50.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Palatin Technologies | 29 |
| CalciMedica | 16 |
| Lipocine | 14 |
| BioVie | 13 |
| NewcelX | 12 |
| Psyence Biomedical | 12 |
| Lexaria Bioscience | 7 |
CYCN News
- 5 months ago - Why is Cyclerion Therapeutics Stock (CYCN) Up Over 160% Today? - TipRanks
- 5 months ago - Cyclerion Therapeutics, Korsana Biosciences enter merger agreement - TheFly
- 5 months ago - Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement - Business Wire
- 6 months ago - Cyclerion receives positive written feedback, responses on CYC-126 study - TheFly
- 6 months ago - Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board - GlobeNewsWire
- 8 months ago - Cyclerion Therapeutics enters exclusive collaboration with Medsteer - TheFly
- 8 months ago - Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression - GlobeNewsWire
- 11 months ago - Cyclerion enters licensing agreement with MIT, announces strategic relaunch - TheFly